Drug Trial Radar · NCT07529535
A First-in-Human Study of ALK-N001 for Injection in Patients With Advanced Solid Tumors
Last checked: Nov 20, 2026Latest source record: Apr 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Suspended
Enrollment
16
Actual
Start
Jun 5, 2025
Primary completion
Dec 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Zhejiang Anglikang Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 14, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a multicenter, open-label, dose-escalation plus rollover and cohort expansion Phase I/II clinical trial conducted in patients with advanced solid tumors, including esophageal squamous cell carcinoma, small cell lung cancer, and gastric/gastroesophageal junction adenocarcinoma. It aims to evaluate the tolerability, safety, pharmacokinetics, and efficacy of ALK-N001 for injection as monotherapy in the treatment of advanced solid tumors such as esophageal squamous cell carcinoma, small cell lung cancer, and gastric/gastroesophageal junction adenocarcinoma.
Conditions
- Advance Solid Tumors
Interventions
ALK-N001 for InjectionDrug
The drug is administered via intravenous infusion at a constant rate . The primary dosing schedule was every 2 weeks (Q2W) in a 28-day cycle, while an every 3 weeks (Q3W) schedule with a 21-day cycle was also explored.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-Limiting Toxicity(DLT)Time frame: Through study completion, an average of 2 years
- Incidence of Adverse Events (AEs)Time frame: Through study completion, an average of 2 years
- Incidence of Serious Adverse Events (SAEs)Time frame: Through study completion, an average of 2 years
- Incidence of AEs Leading to Permanent Treatment DiscontinuationTime frame: Through study completion, an average of 2 years
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Zhejiang Cancer Hospital
Hangzhou, China
Zhongshan Hospital, Fudan University
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.